Johnson & Johnson (NYSE: JNJ) is a solid choice for steady income and strong total return, with a history of dividend increases for over 50 years. The stock delivered a total return of over 60% last year, outperforming the S&P 500 by five times.

The company reported a revenue increase of 6% to $94.2 billion, with earnings per share growing by 90.5% to $11.03. Johnson & Johnson plans to invest $1 billion in a new cell manufacturing facility, part of a $55 billion outlay in U.S. manufacturing, research, and development through early 2029.

With a payout ratio of 46.3% and strong cash flow, Johnson & Johnson has room to continue dividend increases. The company consistently invests in R&D, leading to successful new product launches and solid financial performance. It’s a reliable stock for long-term investors.

Consider Johnson & Johnson for a dependable investment, backed by a 140-year history and a commitment to future growth. The company’s solid financial performance and strategic investments make it a strong choice for investors looking for steady returns over time.

Read more at Yahoo Finance: The Only Healthcare Stock I’d Buy and Never Sell Might Be Johnson & Johnson